Verisk Analytics remains a buy with a $257.44 one-year price target, reflecting a 27.1% upside from current levels. VRSK's recent slump aligns with an industry-wide downturn, not company-specific issues, as evidenced by similar trends in Moody's and Experian. Guidance and analyst estimates project modest growth in 2026, with accelerated earnings expansion and productivity gains expected in 2027 and 2028.
VRSK tops Q4 estimates with 13% EPS growth and higher margins, yet fiscal 2026 revenue and EPS guidance come in below the consensus estimate.
Verisk Analytics, Inc. (VRSK) Q4 2025 Earnings Call Transcript
Verisk Analytics (VRSK) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.6 per share. This compares to earnings of $1.61 per share a year ago.
VRSK readies for fourth-quarter 2025 results, with revenues expected to move up 4.9% on pricing and subscription gains, but EPS likely to dip amid higher costs and taxes.
After a bruising start to the year that has accelerated sharply into February, shares of Verisk Analytics, Inc NASDAQ: VRSK are trading around $170. That means they're down roughly 25% since the end of January, having lost close to 50% from last summer's highs.
Verisk (VRSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
VRSK shares beat industry gains as subscription shift, SaaS demand and new AI tools drive revenue growth across underwriting and claims.
Verisk Analytics, Inc. (VRSK) Presents at UBS Global Technology and AI Conference 2025 Transcript
Verisk (VRSK) reported earnings 30 days ago. What's next for the stock?
Verisk Analytics' shares have dropped 20% since July, improving valuation but still trading at a premium. The company remains a highly focused, profitable data analytics provider for the insurance industry, with EBITDA margins above 50% and near-100% retention rates. The recent $2.35 billion acquisition of AccuLynx adds growth potential but increases leverage and is taking place at a high sales multiple.